Novel mucosal microflora stabiliser (MMS) to fortify the mucosal barrier of different external mucosal tissues of Atlantic salmon under challenging conditions
Atlantic salmon is a key species with more than 2.5 million tonnes, valued at $15.6 billion, farmed annually. However, mucosal infections, particularly those caused by Flavobacterium psychrophilum, pose a major industry challenge, leading to high mortality rates, severe skin and gill damage, and immune suppression. Current treatments, including mechanical, thermal, and chemical methods such as antibiotics, often cause mucosal dysbiosis and weaken fish immunity.
This project aims to develop a novel mucosal microflora stabiliser (MMS) delivered via bath treatment to restore and reinforce the skin and gill microbiota, improving mucosal integrity, immune resilience, and pathogen resistance.